Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Oxaliplatin

Bevacizumab

Leucovorin

Fluorouracil

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folate

Vitamin B9

HAIC combine with Sintilimab and bevacizumab biosimilar

Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.

Q3W

HAIC

Sintilimab

Bevacizumab Biosimilar IBI305

Bin Liang

This is a single-arm, exploratory study to evaluate the efficacy and safety of HAIC in combination with sintilimab and bevacizumab in the first line treatment of patients with BCLC-C hepatocellular carcinoma.

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

An Exploratory Study to Evaluate the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine With Sintilimab and Bevacizumab for BCLC-C Hepatocellular Carcinoma

Defined as a duration from the date of initial treatment to disease progression or death of any cause

Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0

Defined as the incidence of complete response and, partial response

Defined as the incidence of complete response, partial response and stable disease

Defined as a duration from date of initial treatment to disease progression or death in patients who achieve complete or partial response

Defined as a duration from the date of initial treatment to death of any cause.

Wuhan Union Hospital, China

Symptoms and General Pathology

Rare Diseases

Recurrence

Adenocarcinoma, Clear Cell

Adenomyoepithelioma

Epithelial-myoepithelial Carcinoma

Sintilimab 200mg iv., q3w, up to 2 years; Bevacizumab 15mg/kg iv., q3w, up to 22 cycles. Treatment is given until confirmed progression, death, unacceptable toxicity, or any other protocol-specified criterion for withdrawal, whichever occurs first.

Bevacizumab 15mg/kg iv. q3w, up to 22 cycles

Qinglei Gao, PhD, MD

Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims to investigate the potential benefit of combination therapy for patients with OCCC.

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma

The individual participant data will be available (including data dictionaries). The individual participant data that underlie the results reported in this article after deidentification (text, tables, figures, and appendices) in particular will be shared

ORR is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria.

PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.

TTR is defined as the time from the first administration to the first CR or PR recorded. Assessed according to RECIST v1.1 by investigator.

DOR is defined as the time interval from the first record of disease response to disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.

DCR is defined as the proportion of the patients with complete response, partial remission, and stable disease after treatment. Assessed according to RECIST v1.1 by investigator.

OS is defined as the time between enrollment and the patient's death due to any cause.

Safety includes the adverse event profile of sintilimab and bevacizumab according to the Common Terminology Criteria for Adverse Events version 5.0.

Quality of life will be assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and other scales as appropriate.

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

Qilu Hospital of Shandong University

The First Affiliated Hospital of Zhengzhou University

Henan Cancer Hospital

Hubei Cancer Hospital

Shengjing Hospital

Anhui Provincial Cancer Hospital

Wuhan University

Jingzhou Central Hospital

The First People's Hospital of Jingzhou

Xiangyang Central Hospital

Tongji Hospital

Professor

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Amino Acids

Carboplatin

Osimertinib

Pemetrexed

Enzyme Inhibitors

Folic Acid Antagonists

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Folinic Acid

Tyrosine

Bevacizumab, 7.5mg/kg, d1; Pemetrexed, 500mg/m2, d1; Carboplatin AUC5, d1; Osimertinib 80mg/d , d1-21; Q3W/cycle induction therapy for 4 cycle. Then Carboplatin was stopped after 4 cycles, and Osimertinib combined with Bevacizumab and Pemetrexed were given for maintenance treatment every 3 weeks for 2 years. After that, the maintenance treatment of Osimertinib was continued.

Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years

Carboplatin AUC5, d1; was stopped after 4 cycles

Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years

Liang MD Liu, Ph.D

Xiubao MD Ren, Ph.D

This is a single-center, open-label, phase I clinical trial aimed to evaluate the efficacy and safety of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.

Patients received Bevacizumab, 7.5mg/kg d1, Pemetrexed, 500mg/m2, d1 and Carboplatin AUC5, d1; osimertinib 80mg/d , d1-21, Q3W/cycle; induction therapy for 4 cycle, then Carboplatin was stopped after 4 cycles, and osimertinib combined with bevacizumab and pemetrexed were given for maintenance treatment every 3 weeks; Bevacizumab and pemetrexed were discontinued for 2 years; After that, the maintenance treatment of osimertinib was continued

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Phase I Study of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations.

ORR was calculated by the percentage of patients with a confirmed complete (CR) or partial response (PR).

Time from the first use of the study drug to the death of the subject

Progression-free survival is defined as the time from the start of treatment to the first documentation of disease progression or death from any cause, whichever occurs first according to RECIST 1.1.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma	NCT05617430	Hepatocellular ...	HAIC Sintilimab Bevacizumab Bio...	18 Years -	Wuhan Union Hospital, China
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma	NCT04735861	Ovarian Clear C...	Sintilimab Bevacizumab Bio...	18 Years - 75 Years	Tongji Hospital
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma	NCT05617430	Hepatocellular ...	HAIC Sintilimab Bevacizumab Bio...	18 Years -	Wuhan Union Hospital, China
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations	NCT05507606	Non Small Cell ...	Osimertinib Bevacizumab Bio... Carboplatin Pemetrexed	18 Years - 70 Years	Tianjin Medical University Cancer Institute and Hospital
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations	NCT05507606	Non Small Cell ...	Osimertinib Bevacizumab Bio... Carboplatin Pemetrexed	18 Years - 70 Years	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for bevacizumab biosimilar ibi305